I think if the long awaited licensing deal with ICL doesn’t contain an upfront payment like biotechs get when they licence out, or at least a placement to ICL to raise capital, then I think it will be a worry. The last thing the stock needs is another investor presentation, or another trip down under telling us nothing new or even another webcast. Just focus resources on delivering!
Bullish Chart, page-13
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
